NCT02157324View on ClinicalTrials.gov

Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

August 18, 2014

Primary Completion Date

July 20, 2020

Study Completion Date

April 1, 2026

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG

acalabrutinib

DRUG

ACP-319

Trial Locations (3)

37076

Research Site, Hermitage

43210

Research Site, Columbus

76104

Research Site, Fort Worth

Sponsors

Lead Sponsor

Acerta Pharma BV

All Listed Sponsors

lead

Acerta Pharma BV

INDUSTRY